Skip to content

A small patch on the skin. A seizure out of nowhere. A child not meeting milestones. At first, nothing seems connected. But for those with Tuberous Sclerosis Complex, these scattered signs point to one silent force.

TSC is a rare genetic condition that causes tumors to grow in organs like the brain, heart, kidneys, and skin. It affects each person differently.

Some face daily challenges, while others don’t even know they have it. That unpredictability makes TSC hard to catch—and harder to live with.

TSC Global Awareness Day brings the condition into focus. It’s a time when families speak up, turning confusion into clarity. People share what life with TSC really looks like—messy, tough, but also full of strength.

Organizations and doctors join in, pushing for better tools and quicker answers. With more eyes on TSC, the hope is simple: fewer missed signs, more support, and a clear path forward for everyone affected.

TSC Global Awareness Day Timeline

  1. Earliest clinical description of tuberous sclerosis

    English physician John Hilton is reported to have described a patient with seizures and skin lesions later recognized as features of tuberous sclerosis, marking one of the first clinical accounts of the disorder. 

  2. Tuberous sclerosis is formally described

    French neurologist Désiré-Magloire Bourneville publishes a detailed description of patients with brain “tuberous” lesions and epilepsy, giving rise to the term “tuberous sclerosis” and establishing it as a distinct disease.  

  3. Heinrich Vogt’s clinical triad

    German neurologist Heinrich Vogt proposes the classic triad of epilepsy, intellectual disability, and facial angiofibromas as key diagnostic features, shaping early 20th‑century clinical recognition of tuberous sclerosis.  

  4. Autosomal dominant inheritance confirmed

    Genetic studies in families with multiple affected members firmly establish tuberous sclerosis as an autosomal dominant disorder with variable expression, clarifying its hereditary nature and guiding counseling.  

  5. TSC2 gene is identified

    Researchers map and identify the TSC2 gene on chromosome 16, encoding the protein tuberin, a major step in understanding the molecular basis of tuberous sclerosis complex and enabling genetic testing.  

  6. TSC1 gene discovery completes major genetic picture

    Scientists identify the TSC1 gene on chromosome 9, which encodes hamartin, showing that mutations in either TSC1 or TSC2 can cause the disorder and setting the stage for pathway-focused research.  

  7. mTOR pathway and targeted therapy validated

    Seminal work confirms that loss of TSC1/TSC2 function overactivates the mTOR pathway and that mTOR inhibitors like sirolimus can shrink TSC-associated tumors, opening an era of mechanism-based treatments.  

How to Observe TSC Global Awareness Day

TSC Global Awareness Day offers a chance to support those affected by Tuberous Sclerosis Complex (TSC). Here are several engaging ways to participate:

Wear Blue to Show Support

Choose blue clothing or accessories to express solidarity with the TSC community. This simple gesture can spark conversations and increase awareness about the condition.

Share Personal Stories Online

Use social media platforms to share experiences or information about TSC. Posting with hashtags like #TSCGlobalDay can help spread the word and connect with others.

Participate in Fundraising Events

Join local or virtual events such as walks, runs, or bike rides organized to raise funds for TSC research and support services. These activities not only generate resources but also foster community spirit.

Educate Your Community

Organize informational sessions at schools, workplaces, or community centers to educate others about TSC. Providing accurate information can dispel myths and promote understanding.

Support TSC Organizations

Consider donating to organizations dedicated to TSC research and support. Financial contributions can aid in developing treatments and providing resources for those affected.

History of TSC Global Awareness Day

TSC Global Awareness Day started in 2013. A group called Tuberous Sclerosis Complex International (TSCi) created that day.

They connected with organizations across many countries to form a united effort. Their goal was clear—help more people learn about TSC, a rare genetic disorder that causes tumors in different parts of the body.

Before this day existed, TSC remained mostly unknown to the public. Families affected by it often felt isolated.

Doctors sometimes struggled to diagnose it early. TSCi wanted to change that. They believed that sharing personal stories could open eyes and build understanding. So they picked one day each year to raise awareness around the world.

Since its beginning, the event has gained momentum. People now take part in over 50 countries. Supporters wear blue, share facts online, and take part in local events.

Clinics and hospitals use the day to talk about early signs and new treatments. Families post photos, tell their stories, and remind others they aren’t alone.

What began as a small campaign now brings people together across borders. TSC Global Awareness Day continues to grow each year, creating space for connection, learning, and hope.

The message is simple: TSC may be rare, but those affected deserve to be seen and heard.

Facts About TSC Global Awareness Day

Genetic “Two-Hit” Mechanism Behind Tumor Growth

Tuberous sclerosis complex tumors typically arise through a “two-hit” process in which a person inherits or develops a mutation in either the TSC1 or TSC2 gene, then acquires a second, somatic mutation in cells of specific tissues.

Loss of function of the TSC1/TSC2 protein complex removes a critical brake on cell growth, which leads to the development of benign tumors in organs such as the brain, kidneys, heart, and skin.  

Link Between TSC Genes and the mTOR Pathway

The proteins produced by the TSC1 and TSC2 genes form a complex that regulates the mTOR (mechanistic target of rapamycin) signaling pathway, a central controller of cell growth and metabolism.

When this complex is disrupted, mTOR activity becomes abnormally high, which drives excessive cell growth and underlies many of the neurological and organ manifestations seen in tuberous sclerosis complex.   

High Rates of Epilepsy and Early-Life Seizures

About 80 to 90 percent of people with tuberous sclerosis complex develop epilepsy, and seizures often start in infancy, sometimes as infantile spasms.

Early and frequent seizures are strongly linked with worse developmental outcomes, which is why prompt recognition and aggressive seizure management are central to modern TSC care.  

TSC as a Leading Genetic Cause of Autism and Intellectual Disability

Tuberous sclerosis complex is one of the most common single-gene causes of both autism spectrum disorder and intellectual disability.

Studies suggest that roughly 40 to 50 percent of individuals with TSC meet diagnostic criteria for autism, highlighting how disruptions in the TSC1/TSC2–mTOR pathway can alter brain development and social-communication networks.  

Skin Clues That Aid Diagnosis

Distinctive skin changes provide important diagnostic clues for tuberous sclerosis complex.

Features such as hypomelanotic “ash leaf” macules, facial angiofibromas, and shagreen patches occur in most people with TSC and are easily visible on examination, which means dermatologic signs can sometimes be the earliest or only clue that prompts further evaluation for the condition.  

Kidney Tumors and Lifelong Monitoring

Renal angiomyolipomas, a type of benign kidney tumor, occur in up to 80 percent of adults with tuberous sclerosis complex and can cause pain, bleeding, or loss of kidney function if they enlarge.

Because these tumors may grow over time, current guidelines recommend regular kidney imaging and blood pressure monitoring throughout adulthood for people living with TSC.  

Targeted mTOR Inhibitor Treatments

Understanding the role of the mTOR pathway in tuberous sclerosis complex led to the development of targeted drugs such as everolimus and sirolimus.

These mTOR inhibitors can shrink certain TSC-related tumors, including subependymal giant cell astrocytomas in the brain and kidney angiomyolipomas, and are now incorporated into standard treatment options for many patients.  

TSC Global Awareness Day FAQs

You may also like

Jump to main navigationJump to content